Fundraising FoxARCH Venture Partners — 2022 Investments
21 investments dated 2022 · listed companies and verified rows first · show all
IngredientWerks is a molecular farming company that engineers plants to produce plant-based proteins and ingredients for the alternative protein market.
AgTechBiotechFoodTechWoburn, US
Matt Plavan(Chief Executive Officer)inMichael Raab(R&D Lead)Jeremy Schley-Johnson(Vice President)inSteve Snyder(Director)James Schultz(Director)
Board seatClinton Bybee· per SEC Form D
Co-investorsOpen PrairieCultivian Sandbox VenturesSandbox Industries
Dewpoint Therapeutics develops condensate-modulating drugs by using an integrated platform that maps, measures, and modulates biomolecular condensates to identify druggable targets and disease mechanisms.
AI & Machine LearningBiotechDeep TechBoston, US
Richard Young, Ph.D.(Director)inAnthony Hyman, Ph.D.(Director)Tony Hyman(Scientific Co-founder)Rick Young(Scientific Co-founder)Elisabeth Leiderman(Executive Officer)inIsaac Klein, M.D., Ph.D.(Executive Officer)
Co-investorsEcoR1 CapitalGeneral CatalystSamsara BioCapital6 Dimensions CapitalInnovation EndeavorsLeaps by Bayer+6 more
.png)
Pretzel Therapeutics develops therapeutics targeting bioenergetic dysfunction and mitochondrial disease by addressing defects in mitochondrial DNA function and gene expression.
BiotechDeep TechHealthtechMedical Devices
Michal Minczuk(Co-Founder)inGabriel Martinez(Chief Scientific Officer & Co-Founder)Claes Gustafsson(Co-Founder)Maria Falkenberg(Co-Founder)Nils-Göran Larsson(Co-Founder)Gabriel Martinez, Ph.D.(Chief Scientific Officer & Co-Founder)
Co-investorsCambridge Innovation CapitalEIR VenturesAngelini VenturesGV (Google Ventures)HealthCapInvus+2 more
Seattle biotech that developed FDY-5301 for cardiac and skeletal muscle injury; ceased operations in February 2026.
BiotechSeattle, US
Mark Roth(Executive Officer, Director, Promoter)Brian Blackman(Executive Officer)Simon Tulloch(Executive Officer)Stephen Hill(Executive Officer, Director)
BoardPaulina Hill(Director)in
Board seatSteven Gillis· per SEC Form D
Co-investorsOUP (Osage University Partners)Polaris Partners
Boston-area biotech developing gene therapies for genetic causes of pediatric hearing loss.
BiotechCambridge, US
Giampiero De Luca(Director)Jodi A. Cook(Executive Officer, Director)Will McLean(Executive Officer)
Board seatSteve Gillis· per SEC Form D
Co-investorsArkin Capital
Altos Labs develops computational and scientific approaches to reverse disease through breakthrough medicines, operating research institutes focused on cell health, computation, and drug discovery.
BiotechDeep TechLongevityBay Area, US
Richard Murray(CEO and Founder)Shinya Yamanaka(Founder)Hal Barron(CEO and Founder)inRichard Klausner(Founder)Hans Bishop(Founder)Juan Carlos Izpisua Belmonte(Founder)in
Co-investors8VCGeneral CatalystLuma GroupAltitude Ventures Management, Llc
Co-investorsAlta PartnersDC Investment PartnersLongwood FundNextech InvestPathway to CuresAtlas Venture+6 more
Carrick Therapeutics is a biopharmaceutical company with a leadership team experienced in oncology drug development and commercialization.
BiotechDigital HealthHealthtechMedical DevicesBoston, US
Timothy Pearson(CEO)Ash Bahl(CSO)inJenny Horsfield(CBO)inStuart McIntosh(CMO)inDavid Sutherland(VP Finance & Controller)
Co-investorsB Capital GroupB4 CapitalCambridge Innovation CapitalGV (Google Ventures)Lightstone VenturesRevelation Partners+2 more
.jpeg){kind=logo}
Dewpoint Innovations develops functional nanostructured polymeric surfaces for atmospheric water capture, technology originating from PhD research at the University of Sydney.
CleantechClimate TechDeep TechNew Materials
Chiara Neto(Founder & Advisor (Chief Scientific Officer))inMing Chiu(Founder & CTO)in
Co-investorsImpact Ventures Management Pty LtdPacific Channel3E Bioventures CapitalEcoR1 CapitalGeneral CatalystLeaps by Bayer+3 more
Cambridge, MA biotech developing engineered tRNA "protein editing" therapeutics for nonsense-mutation diseases; reported shut down in 2025.
Cambridge, US
Leslie J Williams(Executive Officer, Director)
BoardBenjamin Chen(Director)Seiji Miyahara(Director)inSacha Mann(Director)David Moskowitz(Director)Steven Gillis(Director)in
Co-investors5AM Ventures8VCAtlas VenturePanacea VentureTaiho Ventures, LLCTakeda Ventures
Homeward provides cash offers for home purchases, allowing buyers to make competitive offers without financing contingencies while enabling real estate agents to maintain full commissions.
FintechPropTechAustin, US
Jeff Diehl(Director)Jeffrey Crowe(Director)Srini Palamarthy(Executive Officer)Ben Rubenstein(Director)
BoardTim Heyl(Founder)inKrishna Srinivasan(Director)in
Co-investorsBreyer CapitalEra VenturesHarmony PartnersJavelin Venture PartnersLiveOak VenturesNorwest Venture Partners+3 more
ONI develops the Nanoimager, an automated super-resolution imaging system.
BiotechDeep TechHardwareMedical DevicesOxford, GB
Co-investorsAnjostArtis VenturesFuture Planet CapitalOxford Technology ManagementVertical Venture PartnersAxon Ventures+6 more
Protillion Biosciences develops platform technology for antibody engineering and drug discovery.
AI & Machine LearningBiotechDeep TechCarlsbad, US
Curtis Layton(CEO/Co-Founder)inDavid Walt(Co-Founder)inWill Greenleaf(Co-Founder)inRobert Hollingsworth(Chief Scientific Officer)in
BoardSean Kendall(Director)inMalek Faham(Director)in
Co-investorsIllumina VenturesMerck Global Health Innovation FundMSD Global Health Innovation Fund
Recuro is a virtual-first digital health platform that provides primary care, behavioral health, urgent care, and supplemental benefits (pharmacy, care management, advocacy) to patients, employers, health plans, and providers.
Digital HealthHealthtechSaaSRichardson, US
Michael Brombach(Chief Executive Officer and Co-Founder)inMichael Gorton(Chief Executive Officer)inDr. Kate Sowerwine(Chief Medical Officer)John Halsey(Director)Kris Engskov(Director)inWilliam Paiva(Director)
Co-investors1843 Capital4D CapitalCortado VenturesCure VenturesGlobal Insurance AcceleratorMighty Capital+4 more
Sironax is a biopharmaceutical company focused on the discovery and development of therapies for neurodegenerative, inflammatory and immunological, metabolic, and rare diseases.
BiotechHealthtechLongevityWaltham, US
Dr. Xiaodong Wang(Founder)Dr. Zhiyuan Zhang(Founder)
Co-investorsF-Prime CapitalYuanBio Venture CapitalCBC GroupEight Roads VenturesFuture InnovationGaorong Capital+6 more
Synchron develops brain-computer interface technology delivered via catheter to restore or improve motor and cognitive function in people with impairment or decline.
BiotechDeep TechMedical DevicesCampbell, US
Thomas James Oxley(Executive Officer, Director)Nicholas Opie(Founder)inThomas Oxley(Founder)inTom Oxley(Founder)
BoardRahul Sharma(Director)Alex Morgan(Director)in
Co-investorsAlumni VenturesForepont Capital PartnersID8 InvestmentsK2 GlobalKaleida CapitalKhosla Ventures+15 more
Vilya designs novel macrocycles using AI and computational biology to create medicines that don't exist in nature.
AI & Machine LearningBiotechDeep Tech
David Baker(Founder)Patrick Salveson, PhD(Co-Founder, CTO)Adam Moyer, PhD(Co-Founder, VP of Molecular Design)David Baker, PhD(Nobel laureate, Co-Founder, Director, IPD UW, Prof. Biochemistry)Gaurav Bhardwaj, PhD(Co-Founder, UW, Asst. Prof. Medicinal Chemistry)Lance Stewart, PhD, MBA(Co-Founder, CSO & COO, IPD)
Co-investorsMadrona Venture GroupMenlo VenturesAltitude Ventures Management, LlcAlumni VenturesAtomicChingona Ventures+10 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Apex Neuro Holdings, Inc.High Plains Partners, LLCElephasHappy Health
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.